Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

Elena Rebuzzi, Sara; Signori, Alessio; Luigi Banna, Giuseppe; Maruzzo, Marco; De Giorgi, Ugo; Pedrazzoli, Paolo; Sbrana, Andrea; Andrea Zucali, Paolo; Masini, Cristina; Naglieri, Emanuele; Procopio, Giuseppe; Merler, Sara; Tomasello, Laura; Fratino, Lucia; Baldessari, Cinzia; Ricotta, Riccardo; Panni, Stefano; Mollica, Veronica; Sorarù, Mariella; Santoni, Matteo; Cortellini, Alessio; Prati, Veronica; Josè Soto Parra, Hector; Stellato, Marco; Atzori, Francesco; Pignata, Sandro; Messina, Carlo; Messina, Marco; Morelli, Franco; Prati, Giuseppe; Nolè, Franco; Vignani, Francesca; Cavo, Alessia; Roviello, Giandomenico; Pierantoni, Francesco; Casadei, Chiara; Bersanelli, Melissa; Chiellino, Silvia; Paolieri, Federico; Perrino, Matteo; Brunelli, Matteo; Iacovelli, Roberto; Porta, Camillo; Buti, Sebastiano; Fornarini, Giuseppe

doi:10.1177/17588359211019642

Public

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

Shared by NobleBlocks on Jan 1, 2021 • 12:00 AM UTC

Authors:

Sara Elena Rebuzzi

Alessio Signori

Giuseppe Luigi Banna

Abstract

Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomarkers is still an unmet clinical need. Methods: This multicenter retrospective study investigated the pr...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!